Roquefort Therapeutics plc (ROQAF)

Market Cap	2.07M -45.4%
Revenue (ttm)	n/a
Net Income	-1.21M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,000
Average Volume	6,538
Open	0.0152
Previous Close	n/a
Day's Range	0.0152 - 0.0152
52-Week Range	0.0152 - 0.0214
Beta	-0.56
RSI	n/a
Earnings Date	Apr 27, 2026

About Roquefort Therapeutics

Roquefort Therapeutics plc, a material biotech company, engages in the development of medicines for the treatment of cancer. Its product portfolio consists of five novel patent-protected pre-clinical anti-cancer medicines, which include Midkine antibodies with significance in vivo efficacy and toxicology studies, as well as orphan drug indication; Midkine RNA oligonucleotide therapeutics with novel anti-cancer gene editing action; Midkine mRNA therapeutics for solid tumors; STAT-6 siRNA therapeutics targeting solid tumors with significance in v...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: ROQAF

Financial Performance

Financial numbers in GBP